The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial-Reference-Cited by-同舟云学术

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

Published:2020-06-24 Issue:10 Volume:22 Page:1753-1766
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Arnott Clare¹²³⁴^ORCID,Huang Yuli¹⁵,Neuen Brendon L¹^ORCID,Di Tanna Gian Luca¹⁴,Cannon Christopher P.⁶,Oh Richard⁷,Edwards Robert⁷,Kavalam Mary⁷,Rosenthal Norman⁷,Perkovic Vlado¹⁴,Jardine Meg J¹⁴,Mahaffey Kenneth⁸,Neal Bruce¹⁴⁹¹⁰^ORCID

Affiliation:

1. Cardiovascular Division The George Institute for Global Health, UNSW Sydney Australia

2. Department of Cardiology Royal Prince Alfred Hospital Sydney Australia

3. Sydney Medical School University of Sydney Australia

4. Faculty of Medicine UNSW Sydney Australia

5. Department of Cardiology, Shunde Hospital Southern Medical University (The First People's Hospital of Shunde) Foshan China

6. Cardiovascular Division Brigham & Women's Hospital and Baim Institute for Clinical Research Boston Massachusetts USA

7. Janssen Research & Development, LLC Raritan New Jersey USA

8. Stanford Center for Clinical Research, Department of Medicine Stanford University School of Medicine Stanford California USA

9. The Charles Perkins Centre University of Sydney Sydney Australia

10. Imperial College London London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14091

Reference25 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal B;N Engl J Med.,2017

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

4. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes;Diabetes, Obesity and Metabolism;2024-07-22

2. Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review;Cardiovascular Diabetology;2024-06-26

3. New Perspectives in Management of Cardiovascular Risk Among People With Diabetes;Journal of the American Heart Association;2024-06-18

4. Data Monitoring Committees and clinical trials: From scientific justification to organisation;Therapies;2023-12

5. Comité de surveillance indépendant dans les essais cliniques : de la justification scientifique à l’organisation;Therapies;2023-11